Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rationalized DNA sequencing-based protocol for genotyping patients receiving coumarin therapy.

Scandinavian journal of clinical and laboratory investigation - 1 Sept 2013

Rakicevic Ljiljana B, Kusic-Tisma Jelena S, Kovac Mirjana K, Backovic Dragana T, Radojkovic Dragica P

Abstract excerpt

During the last decade genetic factors affecting coumarin therapy have been extensively investigated. The most important genes appear to be CYP2C9 and VKORC1, and different studies have shown that DNA testing can dramatically improve the safety and effectiveness of the therapy. However, the implementation of pharmacogenetic testing in everyday practice is still not a reality. Facilities and ability to get results...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Coumarins

Share to Cytochrome P-450 CYP2C9

Share to Genotyping Techniques

Share to Multiplex Polymerase Chain Reaction

Share to Thromboembolism

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 23806093
DOI: 10.3109/00365513.2013.809142

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rationalized DNA sequencing-based protocol for genotyping patients receiving coumarin therapy.PMID 23806093Read ↗

Genotype-guided coumarin dosing: where are we now and where do we need to go next?Semantic proximity Read ↗

Pharmacogenetics-based coumarin therapy.Semantic proximity Read ↗

Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.Semantic proximity Read ↗

Pharmacogenetics of Oral Anticoagulant TherapySemantic proximity Read ↗

Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.Semantic proximity Read ↗

Pharmacogenetics and coumarin dosing--recalibrating expectations.Semantic proximity Read ↗

Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No.Semantic proximity Read ↗

Validation of a rapid and inexpensive allele-specific amplification (ASA)-PCR genotyping assay for vitamin K antagonist pharmacogenomics.Semantic proximity Read ↗

Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes.Semantic proximity Read ↗

Pharmacogenomics of 4-hydroxycoumarin anticoagulants.Semantic proximity Read ↗

Frequency Distribution of CYP2C9 and VKORC1 Mutations among Bulgarian Patients and their Importance for Anticoagulant Therapy.Semantic proximity Read ↗

The COAG and EU-PACT trials: what is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.